«We are entirely devoted to prevent, treat and finally hopefully eradicate Alzheimer's disease and other neurodegenerative conditions, by the end of 2025.»

Christoph Hock, MD

Alzheimer’s Disease

An estimated 44 million people of all ages have Alzheimer’s disease (AD) in 2016, and while deaths caused by other major illnesses are continuously declining, deaths caused by neurodegenerative diseases are increasing dramatically. In addition, patient numbers for AD are projected to increase to 115 million by 2050, based on demographic changes in industrialized as well as emerging countries, increasing early diagnoses of these disorders, and increased prevention markets.

Neurimmune aims at the development of disease-modifying treatments for Alzheimer’s disease, and partnered its first RTMTM-derived antibody program Aducanumab (BIIB037) with Biogen in 2007. Aducanumab is a human recombinant monoclonal antibody targeting aggregated forms of beta amyloid, including soluble oligomers and insoluble fibrils deposited into the amyloid plaque in the brain of patients with Alzheimer’s disease. Aducanumab removed amyloid plaques from the brains of patients with early-stage Alzheimer’s disease. Importantly, amyloid plaque reductions occurred in both a dose- and time-dependent manner. There  was also evidence that Aducanumab slowed cognitive decline in these patients in the Phase 1b study (PRIME). Aducanumab is currently being investigated in two global Phase 3 studies (ENGAGE and EMERGE) in early Alzheimer’s disease patients.

In 2010, Neurimmune also partnered its second AD program BIIB076 on recombinant human monoclonal antibodies targeting tau with Biogen.

 

Neurimmune Receives Major Development Milestone upon Initiation of Global Phase 3 Studies with Aducanumab for Early Alzheimer's Disease
Biogen Idec presents positive interim results from 1b study at AD/PD 2015 conference
Aducanumab (BIIB037) for the treatment of Alzheimer's disease reduced brain beta-amyloid levels in a Phase 1b trial
Biogen Idec and Neurimmune announce agreement on three neurodegenerative disease programs
Biogen presents the first clinical data from an ongoing Phase 1 study of Aducanumab (BIIB037) in mild to moderate Alzheimer’s
The Alzheimer’s Association
The World Health Organization